PopED lite: An optimal design software for preclinical pharmacokinetic and pharmacodynamic studies

BACKGROUND AND OBJECTIVE Optimal experimental design approaches are seldom used in preclinical drug discovery. The objective is to develop an optimal design software tool specifically designed for preclinical applications in order to increase the efficiency of drug discovery in vivo studies. METHODS Several realistic experimental design case studies were collected and many preclinical experimental teams were consulted to determine the design goal of the software tool. The tool obtains an optimized experimental design by solving a constrained optimization problem, where each experimental design is evaluated using some function of the Fisher Information Matrix. The software was implemented in C++ using the Qt framework to assure a responsive user-software interaction through a rich graphical user interface, and at the same time, achieving the desired computational speed. In addition, a discrete global optimization algorithm was developed and implemented. RESULTS The software design goals were simplicity, speed and intuition. Based on these design goals, we have developed the publicly available software PopED lite (http://www.bluetree.me/PopED_lite). Optimization computation was on average, over 14 test problems, 30 times faster in PopED lite compared to an already existing optimal design software tool. PopED lite is now used in real drug discovery projects and a few of these case studies are presented in this paper. CONCLUSIONS PopED lite is designed to be simple, fast and intuitive. Simple, to give many users access to basic optimal design calculations. Fast, to fit a short design-execution cycle and allow interactive experimental design (test one design, discuss proposed design, test another design, etc). Intuitive, so that the input to and output from the software tool can easily be understood by users without knowledge of the theory of optimal design. In this way, PopED lite is highly useful in practice and complements existing tools.

• Publication year

  2015

• Venue

  Comput. Methods Programs Biomed.

• Publication date

  2015-05-25

• Fields of study

  Biology, Medicine, Computer Science, Mathematics

• Identifiers
  DOI 10.1016/j.cmpb.2016.02.001arXiv 1505.06658PMID 27000295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methods and software tools for design evaluation for population pharmacokinetics-pharmacodynamics studies.

  2016cited by this paper
• R: A language and environment for statistical computing.

  2014cited by this paper
• Handling Below Limit of Quantification Data in Optimal Trial Design

  2014cited by this paper
• Model-based drug discovery: implementation and impact.

  2013cited by this paper
• Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

  2013cited by this paper
• Ethically Attractive Dose‐Finding Designs for Drugs With a Narrow Therapeutic Index

  2012cited by this paper
• PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

  2012cited by this paper
• Optimized Experimental Design for the Estimation of Enzyme Kinetic Parameters: An Experimental Evaluation

  2012cited by this paper
• Odeint - Solving ordinary differential equations in C++

  2011cited by this paper
• Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment

  2011cited by this paper
• Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0

  2010cited by this paper
• Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications

  2010cited by this paper
• Johan Gabrielsson, Daniel Weiner. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, Fourth Edition

  2010cited by this paper
• Simultaneous optimal experimental design on dose and sample times

  2009cited by this paper
• Model‐based Drug Development

  2007cited by this paper
• A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models

  2007cited by this paper
• Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance.

  2004cited by this paper
• Optimization of Individual and Population Designs Using Splus

  2003cited by this paper
• Rapid determination of glomerular filtration rate by single-bolus inulin: a comparison of estimation analyses.

  1998cited by this paper
• Optimal design in random-effects regression models

  1997cited by this paper
• Optimum Experimental Designs

  1995influential reference
• Optimum experimental designs

  1994cited by this paper
• Drug metabolism and disposition : the biological fate of chemicals.

  1973cited by this paper
• Theory Of Optimal Experiments

  1972cited by this paper
• Some general implicit processes for the numerical solution of differential equations

  1963cited by this paper
• Algol 60 translation : An algol 60 translator for the x1 and making a translator for algol 60

  1961cited by this paper

• Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics

  2024cites this paper
• Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models

  2024cites this paper
• Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice

  2023cites this paper
• Population pharmacokinetics of enrofloxacin and florfenicol in the giant danio (Devario aequipinnatus) following oral administration of both antibiotics and bath administration of enrofloxacin

  2023cites this paper
• Revisiting Nonlinear Bosentan Pharmacokinetics by Physiologically Based Pharmacokinetic Modeling: Target Binding, Albeit Not a Major Contributor to Nonlinearity, Can Offer Prediction of Target Occupancy

  2021cites this paper
• Revisiting nonlinear bosentan pharmacokinetics by PBPK modeling: Target binding, albeit not a major contributor to nonlinearity, can offer prediction of target occupancy

  2021cites this paper
• Anti-microbial and Anti-biofilm activity of a novel Dibenzyl (benzo[d] thiazol-2-yl (hydroxy) methyl) phosphonate by inducing protease expression in Staphylococcus aureus

  2017cites this paper
• Análisis Holístico de Nuevos Desafíos, Paradigmas Tecnológicos y Fundamentos Bioéticos en la Medicina Futurista

  2017influential citation